misetionamide
Phase 1- Indications
- Pancreatic cancer, Ovarian cancer
Company intelligence / Profile preview
Panavance Therapeutics Inc.
Berwyn, Pennsylvania, United Statespanavance.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Interim results from Phase 1 clinical trial of misetionamide in pancreatic cancer show approximately 40% of patients achieved either a partial response or stable disease. The misetionamide-gemcitabine combination demonstrates a very good safety profile and potential therapeutic benefit. Final results are expected in 2025[7].
- Therapeutic areas
- Oncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Panavance Therapeutics Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Panavance Therapeutics Inc..